Petros Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
PTPI$0.07-46.5%Stored close · as of May 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | |
| 3.1 | | Certificate of Amendment to the Certificate of Designations of Series A Convertible Preferred Stock of Petros Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 17, 2024). |
| 3.2* | | Certificate of Amendment to the Certificate of Designations of Series A Convertible Preferred Stock of Petros Pharmaceuticals, Inc. |
| 10.1* | | Form of Amendment Agreement, dated November 13, 2024, by and between Petros Pharmaceuticals, Inc. and the investors party thereto. |
| 10.2+ | | Offer Letter Amendment, effective as of October 16, 2024, by and between the Company and Fady Boctor (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 18, 2024). |
| 10.3 | | Form of Amendment Agreement, dated October 11, 2024, by and between Petros Pharmaceuticals, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 17, 2024). |
| 31.1* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer. |
| 31.2* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer. |
| 32** | | Section 1350 Certification – Principal Executive Officer and Principal Financial Officer. |
| 101 | | The following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Consolidated Financial Statements. |
| 104 | | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
| + | Management contract or compensatory plan or arrangement. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.